133 related articles for article (PubMed ID: 37210766)
21. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
22. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
24. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
Kilburn JM; Lester SC; Lucas JT; Soike MH; Blackstock AW; Kearns WT; Hinson WH; Miller AA; Petty WJ; Munley MT; Urbanic JJ
J Thorac Oncol; 2014 Apr; 9(4):572-6. PubMed ID: 24736084
[TBL] [Abstract][Full Text] [Related]
25. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
[TBL] [Abstract][Full Text] [Related]
26. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
Ni J; Zhou Y; Wu L; Ai X; Dong X; Chu Q; Han C; Wang X; Zhu Z
Radiat Oncol; 2021 Sep; 16(1):177. PubMed ID: 34526044
[TBL] [Abstract][Full Text] [Related]
27. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
[TBL] [Abstract][Full Text] [Related]
28. A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.
Singh AK; Hennon M; Ma SJ; Demmy TL; Picone A; Dexter EU; Nwogu C; Attwood K; Tan W; Hermann GM; Fung-Kee-Fung S; Malhotra HK; Yendamuri S; Gomez-Suescun JA
BMC Cancer; 2018 Nov; 18(1):1183. PubMed ID: 30497431
[TBL] [Abstract][Full Text] [Related]
29. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
30. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Body Radiation Therapy for Salvage Treatment of Recurrent Non-Small Cell Lung Cancer.
Kowalchuk RO; Waters MR; Richardson KM; Spencer KM; Larner JM; Kersh CR
Pract Radiat Oncol; 2020; 10(6):e475-e484. PubMed ID: 32454175
[TBL] [Abstract][Full Text] [Related]
32. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
Bestvina CM; Pointer KB; Karrison T; Al-Hallaq H; Hoffman PC; Jelinek MJ; Juloori A; Melotek JM; Murgu S; Partouche J; Vokes EE; Weichselbaum RR; Pitroda SP; Patel JD; Chmura SJ
J Thorac Oncol; 2022 Jan; 17(1):130-140. PubMed ID: 34500113
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.
Videtic GMM; Donington J; Giuliani M; Heinzerling J; Karas TZ; Kelsey CR; Lally BE; Latzka K; Lo SS; Moghanaki D; Movsas B; Rimner A; Roach M; Rodrigues G; Shirvani SM; Simone CB; Timmerman R; Daly ME
Pract Radiat Oncol; 2017; 7(5):295-301. PubMed ID: 28596092
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
35. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the outcomes of stereotactic body radiotherapy versus surgical treatment for elderly (≥70) patients with early-stage non-small cell lung cancer after propensity score matching.
Dong B; Wang J; Zhu X; Chen Y; Xu Y; Shao K; Zheng L; Ying H; Chen M; Cao J
Radiat Oncol; 2019 Nov; 14(1):195. PubMed ID: 31699115
[TBL] [Abstract][Full Text] [Related]
38. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy.
Ernani V; Appiah AK; Marr A; Zhang C; Zhen W; Smith LM; Ganti AK
J Thorac Oncol; 2019 Mar; 14(3):475-481. PubMed ID: 30503890
[TBL] [Abstract][Full Text] [Related]
40. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC.
Moreno AC; Fellman B; Hobbs BP; Liao Z; Gomez DR; Chen A; Hahn SM; Chang JY; Lin SH
J Thorac Oncol; 2020 Jan; 15(1):101-109. PubMed ID: 31479748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
